Customized Genetic Testing Market Report 2026

The customized genetic testing market size has grown rapidly in recent years. It will grow from $14.13 billion in 2025 to $16.4 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to increasing awareness of hereditary diseases, declining cost of genetic sequencing, expansion of clinical genetic counseling services, rising adoption of predictive testing, growing use of molecular diagnostics.

The customized genetic testing market size is expected to see rapid growth in the next few years. It will grow to $29.5 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising integration of genomics in routine care, expansion of preventive healthcare strategies, growing adoption of precision oncology, increasing investment in genomic data platforms. Major trends in the forecast period include increasing adoption of personalized genetic panels, growing use of ngs-based customized testing, expansion of pharmacogenomic applications, rising demand for targeted risk assessment, enhanced integration of clinical decision support.

The growing adoption of personalized medicine is expected to drive the expansion of the customized genetic testing market in the coming years. Personalized medicine involves tailoring treatments, prevention strategies, and healthcare decisions to the individual characteristics of each patient. This approach is gaining traction due to advances in genomics, proteomics, and biomarker discovery, which allow therapies to be customized based on a patient’s genetic profile, increasing demand for targeted treatments, improved diagnostics, and precision healthcare solutions. Customized genetic testing is central to this trend, providing detailed genetic insights that enable accurate disease risk assessment, targeted therapies, and preventive care. For example, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022, highlighting the growing adoption of personalized medicine and its impact on the market for customized genetic testing.

Leading companies in the customized genetic testing market are increasingly focusing on direct-to-consumer solutions, particularly at-home DNA testing combined with personalized health plans based on individual genetic profiles. At-home DNA testing allows individuals to collect saliva or cheek swab samples outside of clinical settings, typically using kits ordered online or from pharmacies, which are then sent to a laboratory for analysis. For instance, in May 2025, Hydreight Technologies Inc., a Canada-based digital health company, launched a personalized genetic testing and wellness solution on its VSDHOne Platform. This service provides patients with at-home DNA testing kits and delivers customized health plans covering nutrition, fitness, supplementation, and medication compatibility. The platform also supports continuity of care through integrated telehealth services and in-person consultations with licensed healthcare professionals.

In March 2025, Tempus, a U.S.-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. This acquisition aims to strengthen Tempus’ market position and expand its genomic testing capabilities by combining Ambry’s expertise in inherited disease diagnostics with Tempus’ AI-powered precision medicine platform. Ambry Genetics, a U.S.-based company, is a leading provider of clinical genetic testing services, specializing in inherited disease diagnostics, cancer risk assessment, and next-generation sequencing solutions that support precision healthcare.

Major companies operating in the customized genetic testing market are Guardant Health, Tempus, Invitae, 23andMe, Labcorp, Quest Diagnostics, Revvity Omics (PerkinElmer Genomics), Natera, Myriad Genetics, BGI Genomics, CENTOGENE, Veracyte, Fulgent Genetics, LetsGetChecked, Helix, MedGenome, Baylor Genetics, Prenetics, Eurofins (Clinical Genetics), Mapmygenome, Nebula Genomics.

North America was the largest region in the customized genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the customized genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the customized genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the customized genetic testing market by increasing costs of imported sequencing instruments, reagents, consumables, and bioinformatics hardware. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to dependence on imported genomic technologies, while Asia-Pacific faces pricing pressure on test kit exports. These tariffs are increasing test costs and slowing equipment upgrades. However, they are also encouraging local manufacturing of testing reagents, regional sequencing facilities, and domestic innovation in genetic testing technologies.

The customized genetic testing market research report is one of a series of new reports that provides customized genetic testing market statistics, including customized genetic testing industry global market size, regional shares, competitors with a customized genetic testing market share, detailed customized genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the customized genetic testing industry. This customized genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Customized genetic testing is a personalized approach to genetic analysis that adapts the selection of genes, variants, or DNA regions examined to an individual’s specific needs, such as their medical history, family health background, ethnicity, or particular clinical concerns. This testing targets the genes most relevant to the patient’s situation, enabling more accurate risk assessment, diagnosis, and management. It helps detect inherited conditions, guide treatment decisions, and support choices in areas such as disease prevention, reproductive planning, and personalized medicine.

The primary types of customized genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, and pharmacogenomic testing. Predictive testing examines an individual’s genetic profile to evaluate the risk of developing certain hereditary conditions before symptoms appear. This is particularly valuable for conditions that manifest later in life, as it allows for early interventions and informed decision-making. Samples such as saliva, blood, and buccal swabs are analyzed using technologies like next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray analysis, and single-cell sequencing. These tests have applications across oncology, cardiovascular diseases, neurological disorders, and metabolic disorders, and are used for predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, and pharmacogenomic testing.

The customized genetic testing market includes revenues earned by entities by providing services such as personalized testing, diagnostic evaluations, and customized genomic reporting. The market value also includes the worth of related goods supplied by service providers or bundled within their offerings. Only goods and services exchanged between entities or sold directly to end consumers are accounted for in this valuation.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.